Synthetic Biologics Inc (NYSEAMERICAN:SYN) Gets Orphan Drug Designation For VCN-01: Stock Falls

February 9, 2022

Although it is true that the Synthetic Biologics Inc (NYSEAMERICAN:SYN) stock corrected sharply on Tuesday and declined by as much as 4%, it should be noted that in the past week the stock is still up by 8%. It is a diversified clinical stage company and yesterday it had come on to the news cycle following a key announcement. Trading Data On Tuesday, SYN stock moved down 5.10% to $0.27…